Q3 FY2026
Filed Nov 12, 2026Candel reports Q3 2026 net loss of $21.9 million versus $11.3 million a year earlier, with no revenue reported; cash of $203.1 million is stated to fund operations into Q2 2028 and BLA submission is planned for mid-2027
The filing reports no revenue, a widening operating loss (total operating expenses of $22,981 thousand versus $13,207 thousand) and a larger net loss, against clinical and regulatory progress, a cash balance of $203,116 thousand at September 30, 2026 and a company statement that cash funds operations into Q2 2028.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expense, three months ended Sep 30, 2026GAAP | $15.59M | – | – |
| General and administrative expense, three months ended Sep 30, 2026GAAP | $7.39M | – | – |
| Total operating expenses, three months ended Sep 30, 2026GAAP | $22.98M | – | – |
| Loss from operations, three months ended Sep 30, 2026GAAP | −$22.98M | – | – |
| Grant income, three months ended Sep 30, 2026GAAP | $23K | – | – |
| Interest income, three months ended Sep 30, 2026GAAP | $1.82M | – | – |
| Interest expense, three months ended Sep 30, 2026GAAP | −$1.59M | – | – |
| Change in fair value of warrant liabilities, three months ended Sep 30, 2026GAAP | 860K | – | – |
| Total other income (expense), net, three months ended Sep 30, 2026GAAP | $1.11M | – | – |
| Net loss and comprehensive loss, three months ended Sep 30, 2026GAAP | −$21.87M | – | – |
| Net loss per share, basic and diluted, three months ended Sep 30, 2026GAAP | $(0.28) | – | – |
| Research and development expense, nine months ended Sep 30, 2026GAAP | $45.23M | – | – |
| General and administrative expense, nine months ended Sep 30, 2026GAAP | $20.78M | – | – |
| Total operating expenses, nine months ended Sep 30, 2026GAAP | $66.01M | – | – |
| Loss from operations, nine months ended Sep 30, 2026GAAP | −$66.01M | – | – |
| Grant income, nine months ended Sep 30, 2026GAAP | $67K | – | – |
| Interest income, nine months ended Sep 30, 2026GAAP | $4.81M | – | – |
| Interest expense, nine months ended Sep 30, 2026GAAP | −$4.73M | – | – |
| Change in fair value of warrant liabilities, nine months ended Sep 30, 2026GAAP | −3.77M | – | – |
| Total other income (expense), net, nine months ended Sep 30, 2026GAAP | −$3.63M | – | – |
| Net loss and comprehensive loss, nine months ended Sep 30, 2026GAAP | −$69.64M | – | – |
| Net loss per share, basic and diluted, nine months ended Sep 30, 2026GAAP | $(0.98) | – | – |
| Cash and cash equivalents, as of Sep 30, 2026other | $203.1M | – | – |
| Total assets, as of Sep 30, 2026other | $211.1M | – | – |
| Total stockholders' equity, as of Sep 30, 2026other | $131.6M | – | – |
Capital returns
- The filing reports no share repurchases and no dividends for the period.
What drove it
- The company attributes the increase in research and development expense to higher clinical trial and manufacturing costs supporting its aglatimagene programs and an increase in employee-related expenses.
- Research and development expense included non-cash stock compensation of $1.0 million for the third quarter of 2026, compared with $0.5 million for the third quarter of 2025.
- The company attributes the increase in general and administrative expense to higher employee-related expenses and higher commercial readiness costs.
- General and administrative expense included non-cash stock compensation of $1.7 million for the third quarter of 2026, compared with $0.6 million for the third quarter of 2025.
- The company states that the decrease in net other income was primarily related to an increase in interest expense, which was partially offset by higher interest income.
- The company reports that the net loss for the third quarter of 2026 was $21.9 million, compared with $11.3 million for the third quarter of 2025, and includes net other income of $1.1 million and $1.9 million, respectively.
- Clinical data presented at SITC 2026 includes evidence of systemic CD8 positive T cell activation after aglatimagene treatment in the PrTK05 trial, and updated linoserpaturev data in recurrent high-grade glioma with a mOS of 12.0 months in Arms A+B (n=50).
- The company states the BLA for aglatimagene in prostate cancer is currently planned for submission in the middle of 2027, pending the result of its ongoing dialogue with the FDA, due to timelines associated with certain assay refinement.
- The company initiated the first clinical trial site of the global pivotal phase 3 AURORA trial in metastatic non-squamous NSCLC, which it says is expected to enroll across approximately 150 sites worldwide.
Concerns
- The filing reports no revenue or product sales for the quarter or the nine-month period.
- Total operating expenses rose to $22,981 thousand for the quarter from $13,207 thousand a year earlier, and to $66,011 thousand for the nine months from $32,514 thousand.
- The nine-month change in warrant liabilities was $(3,775) thousand, compared with $21,718 thousand in the nine months ended September 30, 2025, which is the line that moved the nine-month other income comparison.
- Interest expense was $(4,730) thousand for the nine months, compared with $(703) thousand a year earlier.
- The accumulated deficit increased to $(300,026) thousand from $(230,387) thousand at December 31, 2025.
- The BLA submission timing is stated as mid-2027 and depends on the outcome of the FDA dialogue. The filing does not state a prior timing for comparison.
- The filing does not state the status of the debt facility or the terms of its tranches beyond a general reference in the forward-looking statements.
What to watch
- The outcome of the ongoing FDA dialogue on the BLA submission for aglatimagene in prostate cancer, which determines the mid-2027 submission timing.
- Operating expense trajectory in R&D and G&A as the company describes ongoing process validation, BLA readiness and commercial readiness work.
- Enrollment progress in the AURORA phase 3 trial, which the filing says is expected to span approximately 150 sites.
- The company's cash runway statement of operations into Q2 2028, measured against the reported cash balance of $203,116 thousand.
- The size and terms of the debt facility generating the interest expense, which the filing does not quantify on the balance sheet.
- Non-cash warrant liability fair value changes, which moved the nine-month other income line between a $(3,775) thousand expense and a $21,718 thousand prior-year income.
Balance sheet and cash flow
- Cash and cash equivalents were $203,116 thousand as of September 30, 2026, compared with $119,731 thousand as of December 31, 2025. The filing does not print a cash flow statement.
- Working capital was $179,965 thousand as of September 30, 2026, compared with $112,392 thousand as of December 31, 2025.
- Total assets were $211,110 thousand as of September 30, 2026, compared with $125,195 thousand as of December 31, 2025.
- Warrant liabilities were $19,373 thousand as of September 30, 2026, compared with $15,598 thousand as of December 31, 2025.
- Total other liabilities were $60,146 thousand as of September 30, 2026, compared with $57,675 thousand as of December 31, 2025.
- Accumulated deficit was $(300,026) thousand as of September 30, 2026, compared with $(230,387) thousand as of December 31, 2025.
- Total stockholders' equity was $131,591 thousand as of September 30, 2026, compared with $51,922 thousand as of December 31, 2025.
- The company states that its existing cash and cash equivalents as of September 30, 2026 are expected to be sufficient to fund operations into Q2 2028 based on current operating plans.
- Interest expense was $(1,591) thousand for the quarter, compared with $(161) thousand a year earlier. The filing does not print the balance or terms of the debt facility that generates it.
Analysis
Candel Therapeutics reported a clinical-stage third quarter with no revenue. Research and development expense rose to $15,587 thousand from $8,461 thousand, and general and administrative expense rose to $7,394 thousand from $4,746 thousand. Total operating expenses were $22,981 thousand against $13,207 thousand a year earlier, and the net loss was $(21,873) thousand, or $(0.28) per share, compared with $(11,269) thousand, or $(0.21) per share. The company attributes the expense growth to higher clinical trial and manufacturing costs for its aglatimagene programs, employee-related costs and commercial readiness work. Stock-based compensation within the operating lines was $1.0 million in R&D and $1.7 million in G&A for the quarter, against $0.5 million and $0.6 million a year earlier.
Below the operating line, interest income was $1,816 thousand against $953 thousand, while interest expense was $(1,591) thousand against $(161) thousand. The company states that the decline in net other income was primarily due to the higher interest expense, partly offset by higher interest income. The change in fair value of warrant liabilities was 860 thousand for the quarter, compared with 1,146 thousand a year earlier. Over the nine months, the warrant line moved to (3,775) thousand from 21,718 thousand, which is why the nine-month net loss of $(69,639) thousand is far larger than the $(8,686) thousand reported a year earlier even though operating expenses rose by a similar scale of change.
The balance sheet shows cash and cash equivalents of $203,116 thousand at September 30, 2026, up from $119,731 thousand at December 31, 2025, with total stockholders' equity of $131,591 thousand against $51,922 thousand. The filing does not include a cash flow statement or a debt balance, so the cause of the cash increase and the size of the debt facility cannot be read from the document. The company states that current cash is expected to fund operations into Q2 2028.
The regulatory and clinical narrative is the main operating update. The company is in ongoing dialogue with the FDA on the BLA for aglatimagene in prostate cancer and now plans submission in the middle of 2027, citing timelines associated with assay refinement. Three SITC posters were presented, including data showing systemic CD8 T cell activation in the PrTK05 trial, and the phase 2a NSCLC results were published. The first site of the phase 3 AURORA trial in NSCLC was initiated, and the company appointed a new director and General Counsel.
The filing contains no revenue, gross margin, segment, non-GAAP or forward financial guidance figures, so there is no prior outlook to test against actual results. The read therefore rests on the expense lines, the net loss, the cash balance and the company's stated regulatory timeline and runway.
Management, verbatim
During the quarter we continued to execute well and make significant progress across the business, as we build the foundation to potentially become a commercial-stage biopharma company.
Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer
We believe we are well positioned to execute our operating plan into Q2 2028.
Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer
Not in the filing
stated, not guessed- Revenue, cost of sales and gross margin: the filing reports no revenue or product sales lines.
- Prior-quarter (Q2 2026) comparisons: the filing does not print second-quarter 2026 figures.
- Percentage or basis-point changes for any reported line: the filing prints the figures but no year-over-year change percentages.
- Cash flow statement: operating cash flow, investing cash flow, financing cash flow and free cash flow are not printed.
- Debt balance, facility terms and tranche details: only interest expense is printed; the debt facility is referenced in the forward-looking statements without figures.
- Balance sheet comparisons for working capital, total assets, warrant liabilities, total other liabilities, accumulated deficit and equity are against December 31, 2025, not a same-period prior year, so prior_year fields are null.
- Non-GAAP measures: none are presented in the filing.
- Prior-period outlook or guidance: no previous outlook was provided, so vs_prior_guidance is empty.
- Segment or program-level financial disclosure: none is provided.
- Consensus estimates and share-price reaction: not provided in the documents.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.